Monograph Capital

Portfolio Co Investors 2026 for Monograph Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Monograph Capital accounts for 11 tracked companies with verified cap-table data, 11 of which disclose round sizes totalling $1.6B. The median disclosed raise is $120M, and the largest is Ollin Biosciences at $330M, ahead of IO Biotech ($250M) and Sudo Biosciences ($188M).

The names that recur most often on these co-invested cap tables are Monograph Capital (11 companies), ARCH Venture Partners (2 companies), Sanofi Ventures (2 companies), Forbion (2 companies), Sofinnova Partners (2 companies), Weatherden (2 companies). By latest disclosed round, the market skews Series A (7), Series B (3), IPO (1).

Best funded Monograph Capital companies

  1. Ollin Biosciences — $330M (latest: Series B)
  2. IO Biotech — $250M (latest: IPO)
  3. Sudo Biosciences — $188M (latest: Series B)
  4. Ascend — $130M (latest: Series A)
  5. Ascend Advanced Therapies — $130M (latest: Series A)
  6. Human Immunology Biosciences — $120M (latest: Series B)
  7. Ouro Medicines — $120M (latest: Series A)
  8. AviadoBio — $97M (latest: Series A)
  9. Maxion Therapeutics — $72M (latest: Series A)
  10. ProLynx — $70M (latest: Series A)
  11. Elevara Medicine — $70M (latest: Series A)

Monograph Capital Holdings Advisors, LLC — related firms and companies (56)

Monograph Capital Holdings Advisors, LLC profile · All research reports